Search

Search Constraints

You searched for: Author/Creator Pannee, Josef

Search Results

1. [P4–152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF β‐AMYLOID (1–42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS. (1st July 2017)

2. [P4–468]: PROGRESS ON THE DEVELOPMENT OF CERTIFIED REFERENCE MATERIALS FOR Aβ1–42. (1st July 2017)

3. [P4–469]: USE FOR CALIBRATION OF CERTIFIED REFERENCE MATERIALS FOR Aβ1–42. (1st July 2017)

4. Corrigendum to "The amyloid-beta degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease" [Neurosci. Lett. 573 (2014) 7–12]. (10th July 2015)

5. Corrigendum to "The amyloid-beta degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease" [Neurosci. Lett. 573 (2014) 7–12]. (10th July 2015)

6. Ex vivo18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway. Issue 1 (December 2017)

7. F1‐05‐03: THE 1946 COHORT: RELATIONSHIPS BETWEEN CEREBRAL AMYLOID PATHOLOGY USING TWO INDEPENDENT METHODS FOR PLASMA AMYLOID BETA MEASUREMENT. (1st July 2019)

8. First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays. Issue 11 (4th August 2020)

9. Fluid‐based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. Issue 4 (12th November 2018)

10. Mass Spectrometry–Based Candidate Reference Measurement Procedure for Quantification of Amyloid-β in Cerebrospinal Fluid. (1st July 2014)